Featured Items |view more
Bridging the Gap Between Medical AI Research and Real-World Clinical Impact
Artificial Intelligence (AI) has tremendous potential to advance healthcare and improve the lives of everyone. But successful clinical translation requires evaluating the performance of AI models on large and diverse real-world datasets.
Our collaboration’s shared vision and commitment will allow researchers and clinicians to continue to work together to discover and provide new approaches to cancer care.
ESMO Congress 2023 Research Highlights
Lung, kidney, and neuroendocrine tumor cancer studies led by Dana-Farber presented at ESMO Congress 2023.
Trials for Hodgkin Lymphoma Patients Who Relapse on Immunotherapies
Classic Hodgkin lymphoma (cHL) is a chemotherapy-sensitive tumor and chemotherapy has been the backbone of treatment for both untreated and relapsed/refractory (R/R) disease
Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker
Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.
Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.